ASX down as biotech company CSL scraps cardiovascular drug trial
The Australian sharemarket fell on Monday after biotech giant CSL dropped its plans to continue with a major drug trial. The benchmark ASX 200 index dropped 0.4 per cent, or 30 points, to finish the session at 7614.90 points. The broader All Ordinaries also fell 0.31 per cent to closeContinue Reading